Kinases as targets: Prospects for chronic therapy

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 5, 2002, Pages 713-717

  Orchard, Sandra ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Inflammatory disease; Kinase inhibitors; Rheumatoid arthritis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOSPORIN A; DORAMAPIMOD; GEFITINIB; IMATINIB; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; RPR 203494; SCIO 469; SPC 105; SPC 25401; SPC 9766; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VX 702; VX 850;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; LONG TERM CARE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STROKE;

ANIMALS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; ENZYME INHIBITORS; HUMANS; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS;

EID: 0036771220     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Cohen P: The role of phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem (2001) 268:5001-5010.
2. Gelfand EW, Weinberg K, Mazer BD, Kadlecek TA, Weiss A: Absence of ZAP-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes. J Exp Med (1995) 182:1057-1065.
3. Kotlyarov A, Yannoni Y, Fritz S, Laass K, Telliez JB, Pitman D, Lin LL, Gaestel M: Distinct cellular functions of MK2. Mol Cell Biol (2002) 22:4827-4835.
4. Sugawara T, Moriguchi T, Nishida E, Takahama Y: Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity (1998) 9:565-574.
5. Revesz L, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Zimmerlin AG: SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg Med Chem Lett (2000) 10:1261-1264.
6. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ: Structural basis of inhibitor selectivity in MAP kinases. Structure (1998) 6:1117-1128. This paper explains how selectivity was achieved against p38 MAP kinases at molecular level.
7. Haddad JJ: VX-745. Curr Opin Investig Drugs (2001) 2:1070- 1076. This evaluation shows how VX-745 achieved proof-of-principle for the treatment of RA.
8. Scios Inc: Scios announces start of phase II clinical trials of new oral treatment for rheumatoid arthritis. Press Release (2002) February 27.
9. Scios Inc: Scios announces positive clinical trial results with oral P38 kinase inhibitor: Phase II trial with company's novel rheumatoid arthritis compound scheduled to begin in second half of year. Press Release (2001) April 30.
10. McLay LM, Halley F, Souness JE, McKenna J, Benning V, Birrell M, Burton B, Belvisi M, Collis A, Constan A, Foster M et al: The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem (2001) 9:537-554.
11. Collis AJ, Foster ML, Halley F, Maslen C, McLay IM, Page KM, Redford EJ, Souness JE, Wilsher NE: RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency. Bioorg Med Chem Lett (2001) 11:693-696.
12. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9:268-272. This paper suggests that p38 MAP kinase inhibitors that do not bind in competition with ATP may reach clinical trials in the near future.
13. Dong C, Yang DD, Toumier C, Whitmarsh AJ, Xu J, Davis RJ, Flavell RA: JNK is required for effector T-cell function but not for T-cell activation. Nature (2000) 405:91-94.
14. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW: SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA (2001) 98:13681-13686.
15. Shin M, Yan C, Boyd D: An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta (2002) 1589:311-316.
16. Han Z, Boyle DL, Chang L, Bennett B, Kahn M, Yang L, Manning AM, Firestein GS. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001 108:73-81.
17. Norman P: Advances in Anti-Arthritic Agents - SMi's Third Annual Conference (Part I), London, UK. IDdb Meeting Report (2002) April 23-24. www.iddb3.com
18. lck in an infant with severe combined immunodeficiency. J Clin Invest (1998) 102:421-429.
19. Kamens JS, Ratnofsky SE, Hirst GC: Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. Curr Opin Investig Drugs (2001) 2:1213-1219.
20. Wilkinson SE, Nixon JS. T-cell signal transduction and the role of protein kinase C. Cell Mol Life Sci 1998 54:1122-1144.
21. Haworth D, Clarkson N, Laber D, Girdwood P, Palmer S, Chaudhary T, Yarwood L, Kelly E, Heys E, Jansson L, Crawley G et al: Characterization of a novel Lck kinase inhibitor. Inflamm Res (2001) 50(Suppl 3):064.
22. Alldred A, Emery P: Leflunomide: A novel DMARD for the treatment of rheumatoid arthritis. Expert Opin Pharmacother (2001) 2:125-137.This paper suggests that long-term kinase suppression may be possible without side effects.